S. Hoog

2.4k total citations
23 papers, 1.7k citations indexed

About

S. Hoog is a scholar working on Pharmacology, Clinical Psychology and Psychiatry and Mental health. According to data from OpenAlex, S. Hoog has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 9 papers in Clinical Psychology and 9 papers in Psychiatry and Mental health. Recurrent topics in S. Hoog's work include Treatment of Major Depression (10 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (6 papers) and Attention Deficit Hyperactivity Disorder (6 papers). S. Hoog is often cited by papers focused on Treatment of Major Depression (10 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (6 papers) and Attention Deficit Hyperactivity Disorder (6 papers). S. Hoog collaborates with scholars based in United States, Netherlands and United Kingdom. S. Hoog's co-authors include Maurizio Fava, Jerrold F. Rosenbaum, Mary Nilsson, John H. Heiligenstein, Jennie G. Jacobson, William B. Krebs, Karen Dineen Wagner, Graham J. Emslie, Eileen Brown and Rajinder Judge and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

S. Hoog

22 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Hoog United States	12	857	832	655	464	198	23	1.7k
J.C. Ballenger United States	19	846 1.0×	809 1.0×	374 0.6×	504 1.1×	156 0.8×	196	2.2k
Sanjeev Pathak United States	22	815 1.0×	1.0k 1.3×	485 0.7×	365 0.8×	267 1.3×	48	2.0k
Shirin Khan United States	13	577 0.7×	442 0.5×	690 1.1×	367 0.8×	87 0.4×	19	1.5k
Mary Nilsson United States	15	547 0.6×	539 0.6×	352 0.5×	238 0.5×	141 0.7×	29	1.1k
Jean‐Pierre Lépine France	21	410 0.5×	625 0.8×	311 0.5×	426 0.9×	98 0.5×	56	1.6k
Arif Khan United States	20	1.3k 1.5×	631 0.8×	827 1.3×	355 0.8×	129 0.7×	42	2.4k
Arifulla Khan United States	23	852 1.0×	324 0.4×	535 0.8×	396 0.9×	67 0.3×	58	1.7k
P E Keck United States	31	2.5k 3.0×	1.7k 2.0×	568 0.9×	366 0.8×	188 0.9×	51	3.9k
S.A. Montgomery United Kingdom	22	1.0k 1.2×	582 0.7×	957 1.5×	659 1.4×	75 0.4×	67	2.1k
Hans‐Jürgen Möller Germany	23	1.2k 1.5×	657 0.8×	467 0.7×	390 0.8×	129 0.7×	65	2.6k

Countries citing papers authored by S. Hoog

Since Specialization

Citations

This map shows the geographic impact of S. Hoog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Hoog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Hoog more than expected).

Fields of papers citing papers by S. Hoog

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Hoog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Hoog. The network helps show where S. Hoog may publish in the future.

Co-authorship network of co-authors of S. Hoog

This figure shows the co-authorship network connecting the top 25 collaborators of S. Hoog. A scholar is included among the top collaborators of S. Hoog based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Hoog. S. Hoog is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu‐Seifert, Hong, Eric Siemers, Karen C. Holdridge, et al.. (2015). Delayed‐start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Alzheimer s & Dementia Translational Research & Clinical Interventions. 1(2). 111–121. 37 indexed citations

Carlson, Christopher, Gopalan Sethuraman, Scott W. Andersen, et al.. (2015). P3‐285: Safety of solanezumab in the expedition‐ext study up to 2 years in a mild to moderate Alzheimer's disease population. Alzheimer s & Dementia. 11(7S_Part_16). 1 indexed citations

Krzyściak, Paweł, et al.. (2013). Chromoblastomycosis as an endemic disease in temperate Europe: first confirmed case and review of the literature. European Journal of Clinical Microbiology & Infectious Diseases. 33(3). 391–398. 23 indexed citations

Hoog, S., et al.. (2013). Duloxetine and Pregnancy Outcomes: Safety Surveillance Findings. International Journal of Medical Sciences. 10(4). 413–419. 27 indexed citations

Heiligenstein, John H., S. Hoog, Karen Dineen Wagner, et al.. (2006). Fluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot Study. Journal of Child and Adolescent Psychopharmacology. 16(1-2). 207–217. 22 indexed citations

Emslie, Graham J., John H. Heiligenstein, S. Hoog, et al.. (2004). Fluoxetine Treatment for Prevention of Relapse of Depression in Children and Adolescents: A Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Child & Adolescent Psychiatry. 43(11). 1397–1405. 102 indexed citations

Emslie, Graham J., John H. Heiligenstein, Karen Dineen Wagner, et al.. (2002). Fluoxetine for Acute Treatment of Depression in Children and Adolescents: A Placebo-Controlled, Randomized Clinical Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 41(10). 1205–1215. 427 indexed citations

Fava, Maurizio, et al.. (2002). Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia. Journal of Clinical Psychopharmacology. 22(2). 137–147. 77 indexed citations

Geller, Daniel, et al.. (2001). Fluoxetine Treatment for Obsessive-Compulsive Disorder in Children and Adolescents: A Placebo-Controlled Clinical Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 40(7). 773–779. 203 indexed citations

10.

Emslie, Graham J., et al.. (2001). Fluoxetine for maintenance of recovery from depression in children and adolescents: A placebo-controlled, randomized clinical trial. European Neuropsychopharmacology. 11. S192–S193. 8 indexed citations

11.

Fava, Maurizio, et al.. (2000). Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. Journal of Affective Disorders. 59(2). 119–126. 105 indexed citations

12.

Fava, Maurizio, et al.. (2000). Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder. The Journal of Clinical Psychiatry. 61(11). 863–867. 190 indexed citations

13.

Fava, M., et al.. (2000). Fluoxetine versus sertraline and paroxetine in major depression: Long‐term changes in weight. International Journal of Gynecology & Obstetrics. 70(S3). 1 indexed citations

14.

Michelson, David, R. Bruce Lydiard, Mark H. Pollack, et al.. (1998). Outcome Assessment and Clinical Improvement in Panic Disorder: Evidence From a Randomized Controlled Trial of Fluoxetine and Placebo. American Journal of Psychiatry. 155(11). 1570–1577. 89 indexed citations

15.

Rosenbaum, Jerrold F., et al.. (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry. 44(2). 77–87. 406 indexed citations

16.

Fava, M., et al.. (1998). 342. Fluoxetine versus sertraline and paroxetine in major depression: Safety and efficacy in anxious and nonanxious subgroups. Biological Psychiatry. 43(8). S103–S103. 1 indexed citations

17.

Fava, Maurizio, et al.. (1998). Fluoxetine versus sertraline and paroxetine in major depression: Tolerability and efficacy in patients with low and high baseline insomnia. European Psychiatry. 13(S4). 269s–269s. 1 indexed citations

18.

Rosenbaum, Jerrold F., et al.. (1998). Fluoxetine versus sertraline and paroxetine in major depression: Efficacy and tolerability in patients with high or low baseline insomnia. European Neuropsychopharmacology. 8. S152–S152. 1 indexed citations

19.

Fava, M., et al.. (1998). A comparison of symptoms following treatment interruption: Evidence from a randomized, double-blind trial with fluoxetine, sertraline, and paroxetine. European Neuropsychopharmacology. 8. S171–S172. 1 indexed citations

20.

Fava, M., James E. Rosenbaum, S. Hoog, William B. Krebs, & John Dillon. (1998). A comparison of symptoms following treatment interruption: Evidence from a randomized, double-blind trial with fluoxetine, sertraline, and paroxetine. European Psychiatry. 13(S4). 204S–205S. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact